Skip to main content
. 2017 Aug 21;26(22):4395–4405. doi: 10.1093/hmg/ddx325

Figure 2.

Figure 2.

Biochemical analyses of 60–78 week-old wild-type and rAAV-treated G6pt−/− mice. (A) Liver microsomal G6P uptake activity in the rAAV-treated G6pt−/− mice is shown at the indicated ages in weeks (W). The mice were grouped based on the gene construct and viral dosages: GPE (n = 6), GPE-low (n = 9), and miGT (n = 15) mice. Two major subgroups emerge for mice expressing 44–62% (G6PT/44–62%, n = 6) and 3–22% (G6PT/3–22%, n = 24), respectively of normal hepatic G6PT activity. The G6PT/44–62% mice included GPE mice and the G6PT/3–22% mice included GPE-low and miGT mice. Hepatic microsomal G6P uptake activity in 60–78 week-old wild-type mice (n = 30) averaged 123 ± 6 units (pmol/min/mg). (B) Hepatic microsomal G6P uptake activity and its relationship to hG6PT mRNA expression and vector genome copy numbers in rAAV-GPE-G6PT- (•, GPE and GPE-low, n = 11–15) and rAAV-miGT-G6PT- (○, miGT, n = 15) treated G6pt−/− mice. (C) Hepatic G6pc mRNA expression and microsomal G6Pase-α enzymatic activity of 60–78-week-old wide-type (+/+, n = 30), G6PT/44–62% (n = 6), and G6PT/3–22% (n = 24) mice. Data represent the mean ± SEM. *P < 0.05, **P < 0.005.